Subject: Social and Behavioral Sciences | Research Article | Drug Licensing and Regulation | Law | Medicine | Health Care Policy | Drug Research and Development | Drug Policy | Q | R | Drugs and Devices | Drug Discovery | Science | Commercial Law | Public Health | Non-Clinical Medicine | Health Economics
mesheuropmc: health care economics and organizations
Australia, like most countries, faces high and rapidly-rising drug costs. There are longstanding concerns about pharmaceutical companies inappropriately extending their monopoly position by “evergreening” blockbuster drugs, through misuse of the patent system. There is,... View more
1 Australian Institute of Health and Welfare (2011) Health expenditure Australia 2009–10. Health and welfare expenditure series no. 46. Cat no HWE 55. Canberra, 2011. Available: http://www.aihw.gov.au/publication-detail/?id=10737420435&tab=2. Accessed 2012 Mar 23.
2 Authors' calculations from publicly-available data on annual expenditure and prescriptions for the Pharmaceutical Benefits Scheme. Available: http://www.health.gov.au/internet/main/publishing.nsf/Content/pbs_expenditure_prescriptions-copy1. Accessed 2012 Mar 23.
3 Aitken M, Berndt ER, Cutler DM (2009) Prescription drug spending trends in the United States: Looking beyond the turning point. Health Aff
8 Parker S, Mooney K (2007) Is “evergreening” a cause for concern? A legal perspective. J Commercial Biotechnology
13 (4) 235–243.
9 Faunce T, Lexchin J (2007) “Linkage” pharmaceutical evergreening in Canada and Australia. Aust and NZ Health Policy
4 (8) Available at: http://www.anzhealthpolicy.com/content/4/1/8. Accessed 23 March 2012.
10 Chalmers R (2006) Evergreen or Deciduous? Australian Trends in Relation to the “Evergreening” of Patents. Melb U L Rev
30 (1) 29–61.